Debjani Grenier

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer

Hyman B. Muss, Donald A. Berry, Constance Cirrincione et al. · New England Journal of Medicine · 2009 · 556 citations · Full text

The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy

Nazanin Fallah‐Rad, Jonathan R. Walker, Anthony Wassef et al. · Journal of the American College of Cardiology · 2011 · 480 citations

Tissue Velocity, Cardiomyopathy, Breast Oncology +11

Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study

Deepa Wadhwa, Nazanin Fallah‐Rad, Debjani Grenier et al. · Breast Cancer Research and Treatment · 2008 · 152 citations

Retrospective Study, Breast Oncology, Medicine +7

Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104

Ann H. Partridge, Laura Archer, Alice B. Kornblith et al. · Journal of Clinical Oncology · 2010 · 126 citations · Full text